RECRUITINGOBSERVATIONAL
Rituximab and Ocrelizumab in Serum With Multiple Sclerosis
Rituximab and Ocrelizumab in Serum With Multiple Sclerosis (ROS-MS)
About This Trial
ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.
Who May Be Eligible (Plain English)
Who May Qualify:
- Included in OVERLORD-MS (NCT04578639)
- Willing to attend laboratory for blood sample collection at scheduled time points
Who Should NOT Join This Trial:
\* Not willing to attend laboratory for blood sample collection at scheduled time points
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Included in OVERLORD-MS (NCT04578639)
* Willing to attend laboratory for blood sample collection at scheduled time points
Exclusion criteria:
\* Not willing to attend laboratory for blood sample collection at scheduled time points
Treatments Being Tested
OTHER
Blood samples for PK
Blood sampled for pharmacokinetic study
OTHER
Blood samples for PK
Blood samples before, shortly after infusion of already assigned/ongoing treatment as well as after 2, 4, 8, 12, 24 weeks for serum conc. measurements.
Locations (1)
Haukeland University Hospital, Deparment of medical biochemistry and pharmacology
Bergen, Vestland, Norway